Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib at different doses in second-line NSCLC with wild type EGFR
NCT01744925Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2012
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01744925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01744925.